Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

"Module 1:~Period 2: participants will receive saruparib orally once daily from Day 1 to Day 9. On Day 5 saruparib will be administered orally in combination with the cocktail of substrates.~Period 3: participants will receive saruparib orally once daily for up to 3 cycles of 28 days each.~Module 2:~Period 1 and Period 2: participants will receive a single oral dose of DC or RC saruparib.~Period 3: participants will receive an oral dose of rabeprazole twice daily from Day 1 to 3, and a single oral dose of rabeprazole prior to DC saruparib on Day 4.~Period 4: participants will receive an oral dose of RC saruparib daily for 3 cycles."

"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."

"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."

"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."

"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."

Period 3: Participants will receive two doses of rabeprazole per day from Day 1 to 3. On Day 4, participants will receive a dose of rabeprazole followed by DC saruparib.